WeVote
Log In

Bill

Bill

SB 484

Insurance: health insurers; compliance with the prescription drug cost and affordability review act; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406z. TIE BAR WITH: SB 0483'23

2023-2024 Regular Session Introduced by Sarah Anthony and 17 co-sponsors

Michigan requires health insurers to comply with prescription drug cost and affordability review standards, potentially addressing rising medication costs through state-level regulatory enforcement mechanisms.

referred to Committee on Insurance and Financial Services
#health:pharmaceuticals #insurance:healthinsurers
0
WeVote Research Nonpartisan
Bill Summary · SB 484

Legislative bill overview

SB 484 amends Michigan's insurance code to require health insurers to comply with the Prescription Drug Cost and Affordability Review Act by adding enforcement provisions under section 3406z. The bill establishes compliance requirements for health insurers regarding prescription drug cost management and review processes, with a companion bill (SB 483) likely addressing related regulatory mechanisms.

Why is this important

Prescription drug costs represent a significant portion of healthcare spending for Michigan residents, and this bill creates explicit legal obligations for insurers to participate in cost containment reviews. The legislation attempts to address rising drug costs by integrating state-level affordability mechanisms into health insurance regulations, potentially affecting drug pricing and access to medications for thousands of policyholders.

Potential points of contention

  • Insurer compliance burden: The bill imposes administrative and operational requirements on health insurers that could increase operational costs, potentially leading to higher premiums or reduced coverage options
  • Interaction with federal law: Prescription drug regulation involves federal Medicare/Medicaid oversight and pharmaceutical patent protections; state-level requirements may create conflicts or compliance complexities
  • Effectiveness unclear: Without seeing the companion bill's specific mechanisms, it's uncertain whether compliance requirements will meaningfully reduce drug costs or simply shift administrative burden between stakeholders (insurers, pharmacies, patients)

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.